利用微環(huán)境神經(jīng)信號(hào)促進(jìn)癌癥發(fā)生的cAMP響應(yīng)程序

1、癌細(xì)胞利用微環(huán)境神經(jīng)信號(hào)反式激活核-線粒體協(xié)同以獲得干性

Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness

Signal Transduction and Targeted Therapy; IF: 39.300; DOI: 10.1038/s41392-023-01487-4

內(nèi)容概要：該研究發(fā)現(xiàn)一項(xiàng)針對(duì)33種TCGA癌癥類(lèi)型的10,852個(gè)樣本的泛癌癥轉(zhuǎn)錄組學(xué)篩查顯示，cAMP應(yīng)答元件（cAMP-responsive element，CRE）轉(zhuǎn)錄因子是癌癥干細(xì)胞的趨同激活因子。聯(lián)合轉(zhuǎn)錄組譜的反卷積、神經(jīng)標(biāo)記的規(guī)范和去甲腎上腺素動(dòng)力學(xué)分析，并經(jīng)scRNA-seq驗(yàn)證，闡明了癌細(xì)胞通過(guò)去甲腎上腺素- ATF1驅(qū)動(dòng)的核-線粒體協(xié)同程序獲得干性，提示通過(guò)劫持微環(huán)境神經(jīng)信號(hào)獲得空間化干性的可能性。

2、基質(zhì)STAT5介導(dǎo)的營(yíng)養(yǎng)活性調(diào)節(jié)造血微環(huán)境因子

Stromal STAT5-mediated trophic activity regulates hematopoietic niche factors

Stem Cells (Dayton, Ohio); IF: 5.200; DOI: 10.1093/stmcls/sxad055

內(nèi)容概要：通過(guò)使用多種骨髓造血和基質(zhì)Cre轉(zhuǎn)基因小鼠株系，發(fā)現(xiàn)信號(hào)轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子5（STAT5a和STAT5b，STAT5ab）敲除會(huì)導(dǎo)致造血干細(xì)胞向粒細(xì)胞分化的啟動(dòng)，同時(shí)會(huì)影響基質(zhì)細(xì)胞的基因表達(dá)和細(xì)胞功能，進(jìn)而影響骨髓微環(huán)境的支持作用。此外，STAT5ab/Cish平衡在基質(zhì)細(xì)胞和造血干細(xì)胞分化中起著關(guān)鍵作用。

3、CD4表型與黑色素瘤患者采用細(xì)胞免疫治療時(shí)腫瘤浸潤(rùn)淋巴細(xì)胞擴(kuò)增減少相關(guān)

CD4 phenotypes are associated with reduced expansion of tumor-infiltrating lymphocytes in melanoma patients treated with adoptive cell therapy

Journal of Immunology; IF: 4.400; DOI: 10.4049/jimmunol.2300250

內(nèi)容概要：通過(guò)RNA-seq和染色質(zhì)免疫沉淀測(cè)序分析CD4+和CD8+腫瘤浸潤(rùn)淋巴細(xì)胞（tumor-infiltrating lymphocyte，TIL）的相關(guān)性，結(jié)合公共scRNA-seq數(shù)據(jù)，發(fā)現(xiàn)輸注CD4+細(xì)胞頻率與輸注TIL的數(shù)量呈負(fù)相關(guān)，輸注TIL的數(shù)量越多，黑色素瘤患者的總生存期越長(zhǎng)。該研究結(jié)果對(duì)于深入了解黑色素瘤患者的TIL擴(kuò)增機(jī)制具有重要意義。

4、FDG攝取反映了免疫富集型甲狀腺癌：基于成像的分子特征的臨床意義

FDG uptake reflects an immune-enriched subtype of thyroid cancer: Clinical implications of imaging-ba[x]sed molecular characterization

Cancer Medicine; IF: 4.000; DOI: 10.1002/cam4.6350

內(nèi)容概要：通過(guò)分析甲狀腺癌的18F FDG PET和RNA-seq數(shù)據(jù)，以及scRNA-seq數(shù)據(jù)，發(fā)現(xiàn)FDG攝取主要發(fā)生在腫瘤微環(huán)境中的免疫細(xì)胞中，F(xiàn)DG攝取可作為免疫富集型甲狀腺癌的標(biāo)志，并為治療分層提供臨床意義。

5、綜合分析RNA-seq數(shù)據(jù)和scRNA-seq數(shù)據(jù)建立基于m6A調(diào)控因子和干細(xì)胞特性的肝細(xì)胞癌預(yù)后模型

Establishment of a prognostic model ba[x]sed on m6A regulatory factors and stemness of hepatocellular carcinoma using RNA-seq data and scRNA-seq data

Journal of Cancer Research and Clinical Oncology; IF: 3.600; DOI: 10.1007/s00432-023-05045-x

內(nèi)容概要：基于RNA-seq數(shù)據(jù)和scRNA-seq數(shù)據(jù)，綜合分析了m6A調(diào)節(jié)因子與肝細(xì)胞癌（hepatocellular carcinoma，HCC）腫瘤干細(xì)胞之間的關(guān)系，發(fā)現(xiàn)了10個(gè)與肝細(xì)胞癌預(yù)后相關(guān)的hub m6A關(guān)鍵調(diào)控因子，并確定調(diào)控因子RBM15B、LRPPRC、IGF2BP1和IGF2BP3可作為有價(jià)值的預(yù)后指標(biāo)以用于指導(dǎo)肝細(xì)胞癌患者的治療。